2-(3-fluoro-4-methylphenyl)acetyl chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-fluoro-4-methylphenyl)acetyl chloride
• 英文别名: 3-fluoro-4-methyl-benzeneacetyl chloride；2-(3-Fluoro-4-methylphenyl)acetyl chloride
• 化学式: C₉H₈ClFO
• 分子量: 186.613
• InChiKey: WBRLOUODOMMUCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-fluoro-4-methylphenyl)acetyl chloride 在 氨 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以4.6 g的产率得到2-(3-fluoro-4-methylphenyl)acetamide
  参考文献：
  名称：

  Discovery and Biological Evaluation of Novel Cyanoguanidine P2X₇ Antagonists with Analgesic Activity in a Rat Model of Neuropathic Pain

  摘要：

  We disclose the design of a novel series of cyanoguanidines that are potent (IC50 similar or equal to 10-100 nM) and selective (>= 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 mu mol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.

  DOI：

  10.1021/jm8015848
• 作为产物：
  描述：

  3-氟-4-甲基苯乙酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-(3-fluoro-4-methylphenyl)acetyl chloride
  参考文献：
  名称：

  Discovery and Biological Evaluation of Novel Cyanoguanidine P2X₇ Antagonists with Analgesic Activity in a Rat Model of Neuropathic Pain

  摘要：

  We disclose the design of a novel series of cyanoguanidines that are potent (IC50 similar or equal to 10-100 nM) and selective (>= 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 mu mol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.

  DOI：

  10.1021/jm8015848

文献信息

• Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases
  申请人：Alcaraz Lilian

  公开号：US20090149448A1

  公开（公告）日：2009-06-11

  The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  本发明涉及用于治疗呼吸系统疾病的取代苯氧乙酸类化合物作为有用的药物化合物，包含这些化合物的药物组合物以及它们的制备方法。
• Identification of ML251, a Potent Inhibitor of <i>T. brucei and T. cruzi</i> Phosphofructokinase
  作者：Kyle R. Brimacombe、Martin J. Walsh、Li Liu、Montserrat G. Vásquez-Valdivieso、Hugh P. Morgan、Iain McNae、Linda A. Fothergill-Gilmore、Paul A. M. Michels、Douglas S. Auld、Anton Simeonov、Malcolm D. Walkinshaw、Min Shen、Matthew B. Boxer

  DOI：10.1021/ml400259d

  日期：2014.1.9

  Human African Trypanosomiasis (HAT) is a severe, often fatal disease caused by the parasitic protist Trypanosoma brucei. The glycolytic pathway has been identified as the sole mechanism for ATP generation in the infective stage of these organisms, and several glycolytic enzymes, phosphofructokinase (PFK) in particular, have shown promise as potential drug targets. Herein, we describe the discovery of ML251, a novel nanomolar inhibitor of T. brucei PFK, and the structure-activity relationships within the series.
• PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES
  申请人：AstraZeneca AB

  公开号：EP1817282A1

  公开（公告）日：2007-08-15
• US8524715B2
  申请人：——

  公开号：US8524715B2

  公开（公告）日：2013-09-03
• [EN] PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES<br/>[FR] DERIVES D'ACIDE PHENOXYACETIQUE UTILES POUR LE TRAITEMENT DES MALADIES RESPIRATOIRES
  申请人：ASTRAZENECA AB

  公开号：WO2006056752A1

  公开（公告）日：2006-06-01

  [EN] The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Formula (I)
  [FR] L'invention concerne des acides phénoxyacétiques substitués utiles en tant que composés pharmaceutiques afin de traiter les troubles respiratoires, des compositions pharmaceutiques contenant lesdits acides et des procédés de préparation desdites compositions. (I)